Lupin’s Q2 margins jumped post launch of the first Spiriva generic in the US, encouraging launch plans for Europe and Canada. With four out of five plants clearing a regulatory overhang from earlier warning letters, the specialty engine is revving up though competition in first-to-file products launched earlier could dampen margins somewhat.

Lupin’s Q2 margins jumped post launch of the first Spiriva generic in the US, encouraging launch plans for Europe and Canada. With four out of five plants clearing a regulatory overhang from earlier warning letters, the specialty engine is revving up though competition in first-to-file products launched earlier could dampen margins somewhat

China’s Bio-Thera Solutions is continuing to pen deals offloading commercialization rights outside of its domestic market to for its BAT2206 biosimilar Stelara (ustekinumab) candidate, this time with Biomm in Brazil.

Takeda spins out Oak Hill Bio, Lupin and Axantia will co-develop filgrastim biosimilar and Xbiome licenses skin ulcer candidate from Aurealis.